Sleep apnoea syndrome - Pipeline Insight, 2024

This “Sleep Apnoea Syndrome - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Sleep Apnoea Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Sleep Apnoea Syndrome Understanding

Sleep Apnoea Syndrome: Overview

Sleep apnea is a serious sleep disorder that occurs when a person's breathing is interrupted during sleep. People with untreated sleep apnea stop breathing repeatedly during their sleep. There are two types of sleep apnea: Obstructive sleep apnea (OSA): The more common of the two forms of apnea, it is caused by a blockage of the airway, usually when the soft tissue in the back of the throat collapses during sleep. Central sleep apnea: Unlike OSA, the airway is not blocked, but the brain fails to signal the muscles to breathe, due to instability in the respiratory control center. All three types of sleep apnea share certain common symptoms: Disrupted breathing in which a person’s respiration can become labored or even stop for up to a minute at a time, Excessive daytime sleepiness, Morning headaches, Irritability, and Limited attention span or difficulty thinking clearly. Treatment aims to normalize breathing during sleep and address any underlying health problems.

Sleep Apnoea Syndrome - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sleep Apnoea Syndrome pipeline landscape is provided which includes the disease overview and Sleep Apnoea Syndrome treatment guidelines. The assessment part of the report embraces, in depth Sleep Apnoea Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sleep Apnoea Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Sleep Apnoea Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Sleep Apnoea Syndrome.

Sleep Apnoea Syndrome Emerging Drugs Chapters

This segment of the Sleep Apnoea Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Sleep Apnoea Syndrome Emerging Drugs

AD128: ApnimedAD128 incorporates a novel norepinephrine reuptake inhibitor. The drug is being evaluated currently in Phase II/III clinical trials for sleep apnoea. The study will evaluate the combination of two drugs AD128 and mannitol, to treat obstructive sleep apnea (OSA) severity.

BAY2586116: BayerBAY2586116 is a new drug under development for the treatment of OSA. It blocks protein channels expressed on the surface of the upper airways in small mechanoreceptors (a type of molecule that sense and pass stimulus outside a cell on to the inside of the cell through mechanical gate on the surface of the cell). Thus the negative pressure reflex alerting the brain of inspiration is triggered more easily leading to a stronger activation of throat muscles. This prevents narrowing or collapse of the upper airways during sleep which is one of the pathological key factors in OSA.

Sleep Apnoea Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Sleep Apnoea Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Sleep Apnoea Syndrome

There are approx. 10+ key companies which are developing the therapies for Sleep Apnoea Syndrome. The companies which have their Sleep Apnoea Syndrome drug candidates in the most advanced stage, i.e. Phase II/III include, Apnimed.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Sleep Apnoea Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sleep Apnoea Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sleep Apnoea Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sleep Apnoea Syndrome drugs.

Sleep Apnoea Syndrome Report Insights

• Sleep Apnoea Syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Sleep Apnoea Syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Sleep Apnoea Syndrome drugs?
• How many Sleep Apnoea Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sleep Apnoea Syndrome?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Sleep Apnoea Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Sleep Apnoea Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 2 business days.